Oncology Voice Network
Join to access to all OVN content. Join for Free
Navigating the Future of CDXs in Oncology
precision oncology companion diagnostics CDx biomarker precision medicine

Navigating the Future of CDXs in Oncology

  • Feb 18th 2026
  • 26 mins
  • Labcorp Perspectives: Oncology

Share This Article

Clips

View Media
Summary

CDX expert Dawn McHugh joins Dr. Rebecca Previs to unpack the role of companion diagnostics in precision oncology and the future of cancer care.

How are companion diagnostics (CDXs) transforming the landscape of precision oncology? In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs welcomes CDX expert Dawn McHugh, Director of Precision Oncology CDx at Labcorp, for a deep dive into the evolving world of companion diagnostics.

You’ll learn what defines a true CDX, how it differs from other biomarker tests, and why integrating it with targeted therapies is essential for matching the right patient to the right treatment. Dawn McHugh guides us through real-world examples—from HER2 and EGFR to the latest in liquid biopsy—explaining how these diagnostics are expanding access, shaping new therapies, and accelerating the pace of cancer innovation. The conversation explores development timelines, regulatory hurdles, the value of early collaboration, and emerging technologies like AI and decentralized NGS.

Whether you’re an oncologist, researcher, or pharma partner, this episode delivers actionable insights on the present and future impact of CDXs in oncology care.

Tune in for a dynamic, forward-looking discussion and gain a new perspective on the science fueling tomorrow’s breakthroughs.

Click for Source

Related Topics

See More Topics

Meet Our Innovation Partners

You May Also Like

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Sep 9th • 5 mins • read
Article
AI-powered real-world evidence: Strategically enhancing value and access
Partner Avatar Envision Pharma Group

AI-powered real-world evidence: Strategically enhancing value and access

Aug 22nd • 5 mins • read
Article
Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?
OVN Avatar Neil Carleton and Priscilla F. McAuliffe

Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?

Dec 1st • 4 mins • read
Article
Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?
OVN Avatar Timothy Qi, Tyler Dunlap, Yanguang Cao1

Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?

Sep 2nd • 10 mins • read
Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Feb 23rd • 8 mins • read
Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Dec 1st • 4 mins • read

Explore OVN

Articles Expert-written insights
Browse Topics Oncology focus areas
OVN Podcast Flagship show
Community Why join OVN